Lung Therapeutics, Inc   Report issue

For profit Phase 1 Phase 2
Founded: Austin TX United States (2013)
Status: Acquired by Aileron Therapeutics (2023)

Organization Overview

First Clinical Trial
2020
NCT04233814
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Lung Therapeutics, Inc